Bridgepoint buys minority stake in Diagnostiskt Centrum Hud

Unquote understands the deal is a proprietary one and is the seventh transaction from Bridgepoint Growth I, which held a final close on £86m in May 2017.

The vehicle focuses on making growth capital investments, typically in businesses with significant UK or Nordic operations, seeking equity investment of €5-20m. 

DCH in 2019 generated revenues of SEK 111m (€11m). The GP will help the company's expansion further into the Nordic region.  

Company
Headquartered in Stockholm and founded in 2012, DCH is an operator of skin clinics and specialises in treating melanoma, psoriasis and other severe dermatology conditions. It has six clinics across four Swedish cities.

The company in 2019 generated revenues of SEK 111m (€11m) and has 11-50 staff, according to LinkedIn. 

People
Bridgepoint Growth – Ann Dahlman (partner).
Diagnostiskt Centrum Hud – Philip Jerlmyr (CEO).

Advisers
Equity – Vinge (legal); KPMG (financial due diligence, tax); Roland Berger (commercial due diligence).
Company – AG Advokat (legal); GT (financial due diligence, tax).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics
• Healthcare
• Bridgepoint
• Sweden
• KPMG